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Abstract
Background: Following tissue injury, monocytes can enter the tissue and differentiate into fibroblast-like cells called
fibrocytes, but little is known about what regulates this differentiation. Extracellular matrix contains high molecular weight
hyaluronic acid (HMWHA; ,2610
6 Da). During injury, HMWHA breaks down to low molecular weight hyaluronic acid
(LMWHA; ,0.8–8610
5 Da).
Methods and Findings: In this report, we show that HMWHA potentiates the differentiation of human monocytes into
fibrocytes, while LMWHA inhibits fibrocyte differentiation. Digestion of HMWHA with hyaluronidase produces small
hyaluronic acid fragments, and these fragments inhibit fibrocyte differentiation. Monocytes internalize HMWHA and
LMWHA equally well, suggesting that the opposing effects on fibrocyte differentiation are not due to differential
internalization of HMWHA or LMWHA. Adding HMWHA to PBMC does not appear to affect the levels of the hyaluronic acid
receptor CD44, whereas adding LMWHA decreases CD44 levels. The addition of anti-CD44 antibodies potentiates fibrocyte
differentiation, suggesting that CD44 mediates at least some of the effect of hyaluronic acid on fibrocyte differentiation. The
fibrocyte differentiation-inhibiting factor serum amyloid P (SAP) inhibits HMWHA-induced fibrocyte differentiation and
potentiates LMWHA-induced inhibition. Conversely, LMWHA inhibits the ability of HMWHA, interleukin-4 (IL-4), or
interleukin-13 (IL-13) to promote fibrocyte differentiation.
Conclusions: We hypothesize that hyaluronic acid signals at least in part through CD44 to regulate fibrocyte differentiation,
with a dominance hierarchy of SAP.LMWHA$HMWHA.IL-4 or IL-13.
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Introduction
After tissue injury, local fibroblasts proliferate to repair the
wound [1,2]. In addition to fibroblasts, bone-marrow-derived
progenitor cells infiltrate the injured site and differentiate into
fibroblast-like cells called fibrocytes [3]. Fibrocytes can differen-
tiate from purified CD14
+ peripheral blood monocytes, but
fibrocytes lose expression of CD14 [4–8]. Other studies also
suggest that fibrocytes differentiate from a population of bone-
marrow derived CD45
+ CXCR4
+ cells found in peripheral blood
[9–11]. Fibrocytes are spindle-shaped cells that express hemato-
poietic cell markers such as MHC class II, CD34, CD45RO,
25F9, and S100A8/A9, stromal cell markers such as collagen I,
and collagen III, and chemokine receptors such as CCR2,
CXCR4, and CCR7 that mediate their entry into the site of
injury [3,9,12–15]. Fibrocytes produce cytokines, collagens,
angiogenic and fibrogenic growth factors, and matrix metallopro-
teinases that help to rebuild tissue after injury [3–5,16–20].
Fibrocytes are found as a circulating population of cells present in
the peripheral blood, and there are elevated numbers of fibrocytes
in patients with inflammatory and fibrotic diseases [10,21,22].
Peripheral blood monocytes generally become macrophages, and
much remains to be understood about the factors that determine
whether or not a monocyte becomes a fibrocyte [23].
During tissue injury, the extracellular matrix component
hyaluronic acid (HA) breaks down into smaller fragments [24–
26]. HA is a negatively charged linear polymer of repeating units
of (b,1–4)-D-glucuronic acid-(b,1–3)-N-acetyl-D-glucosamine that
gives mechanical strength to tissues [27]. High molecular weight
hyaluronic acid (HMWHA) has a molecular mass .1610
6 Da
and is found in normal healthy tissue [28]. The concentration of
hyaluronic acid is 15–150 mg/g in lung tissue, 200 mg/g in the
vitreous humor of the eye, 500 mg/g in skin, and 1400–3600 mg/g
in synovial fluid [29]. In injured tissue, HMWHA breaks down to
low molecular weight HA (LMWHA) [24]. LMWHA masses
range from 0.8 to 8610
5 Da [24]. However, there are variations in
the use of the terms HMWHA or LMWHA. HMWHA often
refers to any hyaluronic acid that has not been degraded [30],
therefore, in this report, we will use HMWHA for hyaluronic acid
that is greater than 1610
6 Da, LMWHA for 0.8 to 8610
5 Da
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3 Da hyaluronic acid.
Cells appear to be able to sense the difference between HMWHA,
LMWHA, and oligo-HA [25,31–37]. For instance, LMWHA but
not HMWHA stimulates alveolar macrophages to secrete
inflammatory cytokines such as IL-8 [25], while the maturation
and activation of monocyte-derived dendritic cells is promoted by
1.2610
3 Da HA, but not HMWHA or LMWHA [36].
One of the major receptors that monocytes and lymphocytes
express to detect HA is CD44 [24,28,38,39]. During lung injury,
CD44 is used to clear degraded HA [25,28,40]. HA-CD44
interactions help the movement of migratory cells during
development and help the migration of immune cells into injured
sites [24,27,41]. HA-CD44 interactions also promote the adhesion
and motility of fibroblasts, thus facilitating tissue repair and
remodeling of the injured sites [42]. Monocytes, dendritic cells,
and lymphocytes also bind HA using Toll-like receptors (TLR)
such as TLR2 and TLR4 [32,33]. LMWHA binds to either TLR2
or TLR4 to elicit pro-inflammatory action, while HMWHA
dampens inflammation by inhibiting TLR2 or TLR4 signaling
[33,43]. HA can also bind CD168 (receptor for hyaluronan-
mediated motility, RHAMM), a cell-surface receptor on fibroblasts
and macrophages [44]. RHAMM is upregulated during inflam-
mation and cancer [44,45]. Finally, HA can also bind lymphatic
vessel endothelial HA receptor (LYVE), which is found predom-
inately in lymphatic endothelial cells and appears to clear HA
from lymph [46].
There are several known factors that either promote or inhibit
fibrocyte differentiation [6–8,47–49]. The pro-fibrotic cytokines
IL-4 and IL-13 potentiate the ability of monocytes to differentiate
into fibrocytes, while the plasma protein serum amyloid P (SAP),
crosslinked IgG, TLR2 agonists, and the pro-inflammatory
cytokines IFN-a, IFN-c and IL-12 inhibit the differentiation of
monocytes to fibrocytes [6–8,47,49]. Since LMWHA increases
during tissue injury [24], in this report we examined the effect of
hyaluronic acid on fibrocyte differentiation. We found that
HMWHA promotes fibrocyte differentiation, while LMWHA
inhibits fibrocyte differentiation.
Materials and Methods
Culturing PBMC with hyaluronic acid, cytokines, SAP, and
antibodies
Blood was collected from healthy adult volunteers with specific
approval from the Institutional Review Boards of Rice University
and Texas A&M University. Written consent was received and all
samples were de-identified before analysis. Peripheral blood
mononuclear cells (PBMC) were isolated and incubated in
RPMI-based serum free media (SFM) as described previously
[7]. High molecular weight hyaluronic acid from rooster comb
(HMWHA) and low molecular weight hyaluronic acid from
umbilical cord (LMWHA) (both from Sigma-Aldrich, St. Louis,
MO) were reconstituted to 25 mg/ml in water. 1,230 Da oligo-
HA (Hyalose, Oklahoma City, OK) was reconstituted to 10 mg/
ml in water. All experiments were performed with at least three
different batches of hyaluronic acid. In some experiments, human
serum amyloid P (SAP) (EMD Biosciences, San Diego, CA),
recombinant human IL-4 (Peprotech, Rockhill, NJ), or recombi-
nant human IL-13 (Peprotech) was also added to the cells. Before
use, SAP was buffer-exchanged as described previously [8]. To
ligate surface receptors, PBMC were cultured in SFM with 2 mg/
ml anti-human CD44 (clone G44-26) (BD Biosciences, San Jose,
CA), anti-human CD44 (clone 515, an antibody that prevents HA
binding to CD44) [41,50] (BD Biosciences), anti-human CD43
(BD Biosciences), or mouse IgG1 isotype control (BD Biosciences).
Dilutions of hyaluronic acid (or an equivalent volume of water as a
control) were made in SFM. Cells were cultured in duplicate wells
of a 96 well tissue culture plate (BD Biosciences). On day 5, fields
of PBMC were photographed using a phase-contrast microscope
with a 206 objective and viable cells counted as described
previously [7]. Cells were then fixed, stained, and the number of
fibrocytes was counted, as described previously [6–8,15,47].
Fibrocytes were identified as adherent spindle-shaped cells with
an oval nucleus as described previously [6,7,15,47].
Treating hyaluronic acid with hyaluronidase
3 mg/ml of HMWHA or 3 mg/ml of LMWHA in PBS were
treated with 10 U/ml of hyaluronidase from Streptomyces hyalur-
olyticus (Sigma-Aldrich) for 1 or 4 hours at 37uC, and the digestion
was stopped by boiling the solution for 5 minutes at 100uC.
Electrophoresis of HA on agarose gels was done following [51]
with the exception that 10 ml of sample was mixed with 5 mlo f6 6
DNA loading buffer [52], and 40 ml of 1 Kb DNA ladder (G5711,
Promega, Madison, WI) was mixed with 10 mlo f6 6DNA loading
buffer [52]. 15 ml of samples or DNA ladder were loaded on the
gel, and this was run at 40 V for 8–10 hours [51]. The gels were
stained with 0.005% Stains-All (Sigma-Aldrich) in 50% ethanol/
water [51]. Dilutions of the digested hyaluronic acids (or PBS as a
control) were made in SFM.
Detecting DNA, RNA, protein, or endotoxin
contamination in HMWHA, LMWHA, or digested HMWHA
1 mg/ml 1 Kb DNA ladder, 10 mg/ml, 1 mg/ml, or 0.1 mg/ml
of HMWHA, LMWHA, or digested HMWHA were electropho-
resed on 1% agarose gels containing 2 mg/ml ethidium bromide
for 2 hours at 40 V. The gels were visualized by UV and
photographed. We also examined 10 ng/ml, 100 ng/ml, or
1000 ng/ml of HMWHA, or digested HMWHA at 260/280 nm
on a Synergy MX (Biotek, Winooski, VT) microplate reader using
a Take3 UV plate to examine the presence of DNA, RNA, or
protein contamination, using BSA as a protein control. The
detection limit of the Synergy MX is 2 ng/ml dsDNA, 2 ng/ml
RNA, or 6 ng/ml protein. We tested for the presence of endotoxin
in digested HMWHA using THP-1 blue cells (Invivogen, San
Diego, CA) and QuantiBlue (Invivogen) following the manufac-
turer’s instructions.
Preparation of monocytes
CD16-negative monocytes were purified from 5610
7 PBMC
using an EasySep Monocyte Depletion Kit (StemCell Technology,
Vancouver, Canada) following the manufacturer’s instructions [7].
To determine the purity of the monocytes, cells were analyzed by
flow cytometry (FACScan, BD Biosciences, or Accuri C6 flow
cytometer, Ann Arbor, MI), as described previously [7,8,15,53]. A
sample of each monocyte preparation was stained with 5 mg/ml
primary antibodies against CD3, CD14, CD16, CD19, and
CD45, and then incubated with FITC-conjugated F(ab9)2 goat
anti-mouse IgG antibodies (cross-adsorbed against human Ig,
Southern Biotechnology, Birmingham, AL, USA) as described
previously [7,8]. Only negatively selected cells in excess of 98%
pure were used, as determined by the positive expression of CD14
and CD45. Less than 1% of the cells showed staining for the T cell
marker CD3, the NK cell marker CD16, or the B cell marker
CD19. 100 ml of purified monocytes at 5610
5 cells/ml in SFM
was mixed with 100 ml of 600 mg/ml HMWHA in SFM, 600 mg/
ml LMWHA in SFM, or a water dilution control. On day 5, the
cells were fixed, stained, and the number of fibrocytes was
counted.
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PBMC were cultured on eight-well glass slides (Lab-Tek, Nalge
Nunc International, Naperville, IL) in the presence or absence of
300 mg/ml HMWHA or SFM for 5 days, as described previously
[53]. Slides were then gently tilted to reduce dislodging cells and
the media was then removed from the corner of the well.
Immunocytochemistry was performed as described previously [53]
with antibodies against CD13 (BioLegend, San Diego, CA), CD14
(BioLegend), CD34 (BD Biosciences), CD45RO (BioLegend),
CXCR4 (R&D Systems, Minneapolis, MN), and collagen I
(Rockland Immunochemicals, Gilbertsville, PA).
Immunofluorescence and staining for hyaluronic acid
PBMC were cultured on eight-well glass slides (Lab-Tek, Nalge
Nunc International, Naperville, IL) for 5 days, as described previously
[8,53]. Slides werethen gently tilted to reduce dislodging cells and the
media was then removed from the corner of the well. 400 mlo fT B S
was then gently added to the wells and then gently pipetted out from
the corner of the well. The cells were then fixed with 200 mlo f2 %
paraformaldehyde(PFA)inPBSfor15 minutesatroomtemperature.
After the PFA was removed, 400 mlo fi c e - c o l dm e t h a n o lw a sa d d e d
to the wells for 1 hour at 4uC to permeabilize the cells. After gently
removing the methanol, 400 ml of TBS was added to the wells for
10 minutes at room temperature and then gently pipetted out from
the corner of the well. This was repeated twice. 400 mlo fT B S
containing 5% BSA (TBS-5% BSA) was then added to the wells at
room temperature for 60 minutes to reduce nonspecific binding.
These PBMC slides were then incubated with 5 mg/ml mouse anti-
human-CD44 (G44-26), rabbit anti-human-RHAMM (clone
EPR4055 Epitomics, Burlingame, CA), or mouse IgG1, isotype
control, at room temperature for 60 minutes. Wellswere washed with
400 ml of TBS, and then incubated with 2.5 mg/ml FITC-conjugated
F(ab9)2 goat anti-mouse or goat anti-rabbit IgG antibodies (Southern
Biotechnology, Birmingham, AL) at room temperature for 30 min-
utes. After washing the slides with TBS, the slides were mounted with
Vectashield mounting media containing DAPI (Vector Laboratories,
B u r l i n g a m e ,C A ) .I m a g e so ft h ec e l l sw e r ec a p t u r e do na nA x i o p l a n 2
microscope (Zeiss) with a CoolSNAP HQ digital camera (Photo-
metrics, Tucson, AZ) and Metamorph software (Molecular Devices,
Dowingtown, PA).
To stain for hyaluronic acid, purified human monocytes were
cultured in the presence or absence of 300 mg/ml HMWHA or
LMWHA in eight-well glass slides as above for 30 minutes. The
media was gently pipetted out and cells were fixed, permeabilized,
and non-specific binding reduced as above. The monocytes were
then incubated with biotinylated hyaluronic acid binding protein
(bio-HABP) (Northstar Associates, East Falmouth, MA) diluted
1:500 in TBS-5% BSA at room temperature for 60 minutes. Wells
were washed with 400 ml of TBS, and then incubated with 1.0 mg/
ml streptavidin-FITC (BD Biosciences) at room temperature for
30 minutes. After washing the slides with TBS, the slides were
mounted as above.
Statistics
Statistical analysis was performed using Prism (GraphPad Software,
San Diego, CA). Statistical significance was defined as p,0.05 as
determined by the statistical methods indicated in the figure legends.
Results
HMWHA potentiates fibrocyte differentiation whereas
LMWHA inhibits fibrocyte differentiation
Hyaluronic acid is a negatively charged glycosaminoglycan that
is abundantly present in extracellular matrix [27,29,33,54,55]. To
investigate the role of hyaluronic acid on fibrocyte differentiation,
PBMC were cultured in the presence of two different sizes of
hyaluronic acid. According to the manufacturer, HMWHA has a
range of molecular masses with a peak at 2610
6 Da and LMWHA
has a range of molecular masses with a peak at 7.5610
5 Da; as
described below, these sizes were verified by gel electrophoresis. In
our serum-free culture media, when PBMC were incubated with
HMWHA or LMWHA, we found that 300 mg/ml HMWHA
potentiated fibrocyte differentiation, whereas 300 mg/ml
LMWHA inhibited fibrocyte differentiation (Figure 1). These data
suggest that HMWHA and LMWHA have opposite effects on
fibrocyte differentiation. All batches of HMWHA and LMWHA
were tested for protein, RNA, DNA, and these were found to be
below the level of detection (data not shown). PBMC treated with
300 mg/ml, 100 mg/ml, 0.03 mg/ml, or 0.01 mg/ml HMWHA or
LMWHA had no significant difference in the number of viable
cells at 5 days compared to untreated cells (Figure 2). These data
suggest that HMWHA and LMWHA have opposite effects on
fibrocyte differentiation without affecting total cell viability.
To confirm that the long spindle-shaped cells are fibrocytes, we
stained day 5 PBMC incubated with 300 mg/ml HMWHA or
SFM for fibrocyte markers such as CD13, CD34, CD45RO,
CXCR4, and collagen I. When PBMC were cultured in the
presence of 300 mg/ml HMWHA or SFM for 5 days, the long
spindle-shaped cells stained positively for CD13, CD34,
CD45RO, CXCR4, and collagen I (data not shown). We also
stained the day 5 PBMC cultured in 300 mg/ml HMWHA or
SFM for the monocyte marker CD14 and the macrophage marker
PM2K. Fibrocytes from both conditions did not stain for CD14 or
PM2K (data not shown). There were few non-fibrocyte cells that
stained positively for CD14 and PM2K (data not shown).
Figure 1. High molecular weight hyaluronic acid (HMWHA)
promotes fibrocyte differentiation, while low molecular weight
hyaluronic acid (LMWHA) inhibits fibrocyte differentiation.
Human PBMC were cultured in the indicated concentrations of HMWHA
and LMWHA. After 5 days, the cells were air dried, fixed, stained, and the
number of fibrocytes was counted. Fibrocytes were identified as
adherent spindle-shaped cells with an oval nucleus. For each donor,
values were calculated as the percent of the no-HA control. The results
are mean 6 SEM (n=6 separate experiments for HMWHA and n=5
separate experiments for LMWHA). The number of fibrocytes per
2.5610
5 PBMC for the no-HA controls from the 6 donors was 808, 400,
296, 450, 850, and 1200. * indicates p,0.05 and ** p,0.01, compared
to control as determined by t-test. Using the non-parametric Mann
Whitney two-tailed t-test, 300 mg/ml and 100 mg/ml HMWHA signifi-
cantly increases the number of fibrocytes when compared to control
with p,0.001, and 300 mg/ml LMWHA significantly decreases the
number of fibrocytes when compared to control with p,0.01.
doi:10.1371/journal.pone.0026078.g001
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cells are fibrocytes.
Hyaluronidase treated HA inhibits fibrocyte
differentiation
Since HMWHA potentiated fibrocyte differentiation and
LMWHA inhibited fibrocyte differentiation, it is possible that
HMWHA contains a contaminant that potentiates fibrocyte
differentiation, or LMWHA contains a contaminant that inhibits
fibrocyte differentiation. To confirm that hyaluronic acid of
different sizes have different effects, we digested HMWHA into
smaller fragments with hyaluronidase to determine if digested
HMWHA inhibits fibrocyte differentiation. HMWHA had a range
of molecular mass of approximately 6.3610
6 Da–2610
6 Da
(Figure 3A). The size range of the HMWHA digested with
hyaluronidase was equivalent to the size of LMWHA (a mass
range of approximately 6610
5 Da–8610
5 Da) as analyzed by gel
electrophoresis, while hyaluronidase treatment of LMWHA
slightly decreased the upper end of the size range of the LMWHA
(Figure 3A). Hyaluronidase may have digested the HMWHA and
LMWHA into smaller sizes such as oligo hyaluronic acid.
However, we were unable to detect these smaller sizes on the
gel. Hyaluronidase-treated HMWHA and LMWHA inhibited
fibrocyte differentiation (Figure 3B). Hyaluronidase-containing
PBS had no effect on fibrocyte differentiation (data not shown).
Since HMWHA were digested with bacterial hyaluronidase, it is
possible that the digested HMWHA may contain endotoxins that
are actually causing the inhibition of fibrocyte differentiation.
Hyaluronidase digested HMWHA always had endotoxin below
detectable levels (data not shown). Treatment of PBMC with
HMWHA and LMWHA digested with hyaluronidase also did not
affect cell viability at 5 days (data not shown). Together, this
suggests that the potentiation of fibrocyte differentiation by
HMWHA and the inhibition of differentiation by LMWHA are
not due to a non-HA contaminant.
High and low molecular weight HA are present at sites of
injury [24,34,56]. We therefore examined how combinations of
300 mg/ml HMWHA and 300 mg/ml LMWHA affect fibrocyte
differentiation. The number of fibrocytes observed in PBMC
treated with a combination of HMWHA and LMWHA was
significantly lower compared to PBMC cultured with HMWHA
alone, but not significantly different compared to PBMC
cultured with LMWHA alone (Figure 4). In this experiment,
we added 2.7 times more moles of LMWHA than HMWHA. It
is possible that the increased amount of LMWHA that we added
neutralized the effect of HMWHA on fibrocyte differentiation.
When we analyze the data with Mann Whitney one-tailed t-tests,
we observe that 300 mg/ml HMWHA or 300 mg/ml LMWHA
are significantly different from the combination of 300 mg/ml
HMWHA and LMWHA, which suggests that HMWHA and
LMWHA both neutralize each other’s effect on fibrocyte
differentiation.
HMWHA and LMWHA directly affect the differentiation of
monocytes to fibrocytes
We previously found that IL-12 and TLR2 agonists, when
added to a population of PBMC, indirectly affect monocyte to
fibrocyte differentiation [7,8], while factors such as SAP, IL-4, IL-
13, or aggregated IgG directly affect monocyte to fibrocyte
differentiation [6,8,47]. Therefore, we examined whether
HMWHA or LMWHA act directly on human monocytes. When
300 mg/ml HMWHA or LMWHA were added to purified
monocytes, HMWHA potentiated fibrocyte differentiation while
LMWHA inhibited fibrocyte differentiation (Figure 5). This
suggests that HMWHA and LMWHA act directly on monocytes
to either potentiate or inhibit fibrocyte differentiation.
Oligo hyaluronic acid has no effect on fibrocyte
differentiation
Since LMWHA and hyaluronidase-treated HMWHA de-
creased the number of fibrocytes, we investigated the possibility
that very small hyaluronic acid polymers might inhibit fibrocyte
differentiation. When PBMC were cultured with increasing
concentrations of 6-mer oligo hyaluronic acid (1,230 Da), there
was no difference in the number of fibrocytes compared to SFM
(Figure 6). This indicates that although LMWHA inhibits
fibrocyte differentiation, the effect requires a polymer larger
than a 6-mer/1,230 Da hyaluronic acid. This also suggests that
hyaluronidase digested HMWHA inhibited fibrocyte differentia-
tion (Figure 3B) due to a size that is similar to LMWHA, and not
because of the small fragment sizes that are similar to oligo
hyaluronic acid.
HMWHA and LMWHA have different effects on the
expression of CD44
Hyaluronic acid binds to the cell-surface molecule CD44, and
this interaction plays an important role in development,
inflammation, tumor growth, and the recruitment and activation
of many immune cells into injured tissues [57]. Therefore we
tested the effect of HMWHA and LMWHA on the expression of
CD44 on PBMC. After culturing PBMC in the presence or
absence of 300 mg/ml of HMWHA or 300 mg/ml of LMWHA for
5 days, cells were stained for CD44. For PBMC cultured in SFM,
both fibrocytes and non-fibrocyte cells expressed CD44 (Figure 7).
In cultures containing HMWHA, fibrocytes and non-fibrocyte
cells showed staining for CD44 similar to the control (Figure 7). In
cultures containing LMWHA, both fibrocytes and non-fibrocyte
cells had less staining for CD44 compared to the control (Figure 7).
These results indicate that not only do HMWHA and LMWHA
have opposite effects on fibrocyte differentiation, but they also
have different effects on the levels of CD44 on fibrocytes and non-
fibrocyte cells.
Figure 2. HMWHA and LMWHA do not affect cell viability.
Human PBMC were cultured in the absence (SFM) or presence of the
indicated concentrations of HMWHA or LMWHA for 5 days. After 5 days,
the number of cells was counted. The results are mean 6 SEM of viable
cells per 0.15 mm
2 (n=4 separate experiments). There was no statistical
significance as analyzed by ANOVA or t-test.
doi:10.1371/journal.pone.0026078.g002
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differentiation
To determine whether the hyaluronic acid binding receptor
CD44 could directly affect fibrocyte differentiation, we cultured
PBMC with two different anti-human CD44 antibodies, anti-
human CD43, or mouse IgG1 isotype control for 5 days. We used
CD43 as a second hematopoietic marker as it plays an important
role in adhesion, cell-signaling, and cytoskeleton interactions, but
does not bind HA [58]. One of the anti-human CD44 antibodies
(clone 515) is a blocking antibody that binds at or near the same
site as HA on CD44, preventing HA from binding to CD44
[41,50]. The second CD44 mAb (clone G44-26) does not prevent
HA binding to CD44. When added to PBMC, both CD44
antibodies significantly increased the number of fibrocytes
compared to PBMC cultured in either SFM or mouse IgG1
antibodies (Figure 8). Anti-human CD43 and mouse IgG1 isotype
control antibodies had no statistically significant effect on fibrocyte
differentiation.
HA can also bind to other surface receptors such as RHAMM
[59,60]. We examined if HMWHA or LMWHA affect the
expression of RHAMM. After culturing PBMC in the presence or
absence of 300 mg/ml of HMWHA or 300 mg/ml of LMWHA for
5 days, cells were stained for RHAMM. As described previously in
activated monocytes [61] or CD34
+ cells [62], we did not observe
any staining for RHAMM in fibrocytes or non-fibrocyte cells in
the presence or absence of HMWHA or LMWHA (data not
shown).
Purified monocytes internalize HMWHA and LMWHA
As HMWHA and LMWHA directly affect the differentiation
of monocytes to fibrocytes, we examined if the internalization
of HMWHA and LMWHA was different in purified monocytes.
Purified monocytes were incubated with or without 300 mg/ml
of HMWHA or 300 mg/ml of LMWHA, and after 30 minutes
t h ec e l l sw e r ef i x e d .T h ef i x ed cells were then stained for
hyaluronic acid. We detected a low intensity fluorescence signal
on untreated monocytes, which could have been due to
autofluorescence, non-specific binding of the biotinylated
hyaluronic acid binding protein (bio-HABP), or the presence
of HA bound to the cells ex vivo, as these were freshly prepared
cells, and HA is present in plasma at 0.01–0.03 mg/ml [63]. We
observed HA staining inside HMWHA and LMWHA treated
monocytes (Figure 9). Monocytes treated with HMWHA or
LMWHA for 60 minutes also had HA staining inside the cells
(data not shown). This suggests that the opposite effect of
HMWHA and LMWHA on fibrocyte differentiation is unlikely
Figure 3. HMWHA and LMWHA treated with hyaluronidase inhibit fibrocyte differentiation. (A) HMWHA and LMWHA were treated with
10 U/ml of hyaluronidase for 1 and 4 hours at 37uC. Samples were analyzed by agarose gel electrophoresis. M, 1 Kb ladder; Lane 1, HMWHA; Lane 2,
HMWHA incubated with hyaluronidase for 1 hour; Lane 3, HMWHA incubated with hyaluronidase for 4 hours; Lane 4, LMWHA; Lane 5, LMWHA
incubated with hyaluronidase for 1 hour; Lane 6, LMWHA incubated with hyaluronidase for 4 hours; Lane 7, PBS; Lane 8, PBS incubated with
hyaluronidase for 1 hour; and Lane 9, PBS incubated with hyaluronidase for 4 hours. (B) Human PBMC were cultured in 300 mg/ml of 4 hours-
hyaluronidase-treated or untreated HMWHA and LMWHA. After 5 days, the cells were air dried, fixed, stained, and the number of fibrocytes was
counted. The results are mean 6 SEM of SFM percent control (n=6 separate experiments). The number of fibrocytes in SFM controls from the 6
donors was 883, 1029, 808, 288, 400, and 288. * indicates p,0.05, ** p,0.01, *** p,0.001 as determined by t-test. Using the non-parametric Mann
Whitney two-tailed t-test, 300 mg/ml HMWHA significantly increases the number of fibrocytes when compared to control with p,0.001, but 300 mg/
ml hyaluronidase incubated HMWHA is not significantly different from control. Also, 300 mg/ml LMWHA significantly decreases the number of
fibrocytes when compared to control with p,0.001, and 300 mg/ml hyaluronidase incubated LMWHA also significantly decreases the number of
fibrocytes when compared to control with p,0.001. Using the non-parametric Mann Whitney one-tailed t-test, 300 mg/ml hyaluronidase incubated
HMWHA significantly decreases the number of fibrocytes when compared to control with p,0.05.
doi:10.1371/journal.pone.0026078.g003
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molecular weight hyaluronic acids by purified monocytes.
Although ten-day cultured fibrocytes synthesize hyaluronic acid
[64], our inability to detect hyaluronic acid on monocytes
cultured for 60 minutes suggest that hyaluronic acid production
in fibrocytes is developmentally regulated.
SAP inhibits HMWHA-induced fibrocyte differentiation
and potentiates LMWHA-induced fibrocyte inhibition
A variety of pro-fibrocyte and anti-fibrocyte factors are
present during tissue injury [8,24,48,49,65]. We investigated
the effect of HMWHA and LMWHA on fibrocyte differenti-
ation in the presence of SAP, a potent inhibitor of fibrocyte
differentiation [6,8,15,53,66–69]. PBMC were cultured in
different concentrations of HMWHA or LMWHA along with
different concentrations of SAP. SAP counteracted HMWHA-
induced fibrocyte differentiation, and potentiated LMWHA-
induced fibrocyte inhibition (Figure 10). This suggests that the
fibrocyte-inhibiting activity of SAP has a dominant effect over
the fibrocyte-promoting activity of HMWHA, and that
LMWHA potentiates the ability of SAP to inhibit fibrocyte
differentiation.
LMWHA inhibits IL-4 or IL-13-induced fibrocyte
differentiation
IL-4 and IL-13 are cytokines that potentiate fibrocyte
differentiation [6,8,53]. To determine if there is a regulatory
hierarchy, we examined the effect of LMWHA on fibrocyte
differentiation in the presence of IL-4 or IL-13. IL-4 and IL-13
promoted fibrocyte differentiation, and LMWHA inhibited IL-4-
and IL-13-induced fibrocyte differentiation (Figure 11). This
suggests that the fibrocyte inhibiting activity of LMWHA has a
Figure 4. LMWHA inhibits HMWHA-induced fibrocyte differen-
tiation. Human PBMC were cultured in SFM (control), SFM with
300 mg/ml HMWHA, SFM with 300 mg/ml LMWHA, or SFM with 300 mg/
ml HMWHA and 300 mg/ml LMWHA. After 5 days, the cells were air
dried, fixed, stained, and the number of fibrocytes was counted. The
results are mean 6 SEM of percent of control (n=3 separate
experiments). The number of fibrocytes per 2.5610
5 PBMC in controls
from the 3 donors was 1525, 713, and 1290. * indicates p,0.05,
** p,0.01, *** p,0.001 compared to control as determined by ANOVA.
Using the non-parametric Mann Whitney two-tailed t-test, there is no
statistical significant difference among different experimental groups.
Using the non-parametric Mann Whitney one-tailed t-test, 300 mg/ml
HMWHA significantly increases the number of fibrocytes when
compared to control with p,0.05, 300 mg/ml LMWHA significantly
decreases the number of fibrocytes when compared to control with
p,0.05, 300 mg/ml HMWHA and 300 mg/ml LMWHA significantly
decreases the number of fibrocytes when compared to control with
p,0.05. Additionally, 300 mg/ml HMWHA significantly increases the
number of fibrocytes when compared to 300 mg/ml LMWHA or the
combination of 300 mg/ml HMWHA and LMWHA with p,0.05. 300 mg/
ml LMWHA significantly decreases the number of fibrocytes when
compared to 300 mg/ml HMWHA or the combination of 300 mg/ml
HMWHA and LMWHA with p,0.05.
doi:10.1371/journal.pone.0026078.g004
Figure 5. HMWHA potentiates but LMWHA inhibits the
differentiation of purified monocytes to fibrocytes. Purified
human monocytes were cultured in 300 mg/ml of either HMWHA or
LMWHA for 5 days. After 5 days, the cells were air dried, fixed, stained,
and the number of fibrocytes was counted. The results are mean 6 SEM
of percent no-HA control (n=3 separate experiments). The number of
fibrocytes per 2.5610
5 monocytes in controls from the 3 donors was
4250, 2450, and 1600. * indicates p,0.05 and ** indicates p,0.01
compared to control as determined by t-test. Using the non-parametric
Mann Whitney two-tailed t-test, there is no significant difference among
the control, 300 mg/ml HMWHA, or 300 mg/ml LMWHA. Using the non-
parametric Mann Whitney one-tailed t-test, 300 mg/ml HMWHA
significantly increases the number of fibrocytes when compared to
control, 300 mg/ml LMHWA significantly decreases the number of
fibrocytes when compared to control.
doi:10.1371/journal.pone.0026078.g005
Figure 6. Oligo hyaluronic acid does not affect fibrocyte
differentiation. Human PBMC were cultured in different concentra-
tions of oligo hyaluronic acid for 5 days. After 5 days, the cells were air
dried, fixed, stained, and the number of fibrocytes was counted. The
results are mean 6 SEM of percent control (n=3 separate experiments).
The number of fibrocytes 2.5610
5 PBMC in controls from the 3 donors
was 4150, 2560, and 575.
doi:10.1371/journal.pone.0026078.g006
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IL-13.
Discussion
We found that 300 mg/ml HMWHA potentiates fibrocyte
differentiation and 300 mg/ml LMWHA inhibits fibrocyte differ-
entiation. These HA concentrations are similar to what has been
observed in tissues [29], and the HA concentrations used in other
studies [25,28,33,70,71]. The effect of these two different sizes of
hyaluronic acid on fibrocyte differentiation is a direct effect on
monocytes. HMWHA and LMWHA also have different effects on
the levels of the adhesion receptor CD44. The opposite effect of
HMWHA and LMWHA on fibrocyte differentiation does not
appear to be due to the difference in the internalization of
HMWHA and LMWHA by monocytes. Anti-human CD44
antibodies potentiate fibrocyte differentiation, suggesting that
CD44 may at least in part mediate the effect of hyaluronic acid
on fibrocyte differentiation. SAP inhibits HMWHA-induced
fibrocyte differentiation and potentiates LMWHA-induced fibro-
cyte differentiation, while LMWHA inhibits IL-4- or IL-13-
potentiated fibrocyte differentiation. These results suggest a
dominance hierarchy of SAP.LMWHA$HMWHA.IL-4 or
IL-13.
HMWHA and LMHWA bind to CD44, TLR2, TLR4, LYVE,
and RHAMM (CD168) receptors to accomplish their biological
effects [56]. We have previously shown that TLR2 and TLR4
agonists do not have a direct effect on monocyte to fibrocyte
differentiation [7]. Therefore, it is unlikely that HWMHA and
LMWHA regulate fibrocyte differentiation via TLR2 or TLR4.
We and others have also failed to detect RHAMM expression on
fibrocytes or human monocytes cultured ex vivo, although
macrophage cell lines express RHAMM [61,62]. Finally LYVE
is a HA receptor expressed predominately by lymphatic
endothelium [46], and we have not detected LYVE on monocytes,
macrophages, or fibrocytes (data not shown) [53]. As antibodies
against CD44 potentiated fibrocyte differentiation, CD44 appears
to be the dominant receptor for HA induced regulation of
fibrocyte differentiation.
Several studies have described differential effects of HMWHA
and LMWHA on different types of cells such as macrophages,
dendritic cells, osteoclasts, and T cells [25,32–37]. For example, in
murine and human macrophages, HMWHA (6610
6 Da) did not
affect the secretion of pro-inflammatory chemokines or cytokines
[25], while LMWHA (,5610
5 Da) stimulated these cells to
produce inflammatory chemokines such as macrophage inflam-
matory protein-1a (MIP-1a), macrophage inflammatory protein-
1b (MIP-1b), and monocyte chemoattractant protein-1 (MCP-1)
[25,32,72,73]. In cultured macrophages, HMWHA (4.6610
5–
2.8610
6 Da) inhibited phagocytosis, while LMWHA (9.06
10
4 Da) enhanced phagocytosis [71]. The inhibition of macro-
phage phagocytosis was proportional to the molecular weight of
the HA. These results suggest that LMWHA (,5610
5 Da)
actively stimulate many types of cells at sites of injury to facilitate
the clearance of debris and infectious agents, while HMWHA
(.10
6 Da), which is the dominant HA in resolving wounds, acts as
a signal for repair.
During tissue injury, cirrhosis, and fibrosis, the concentration of
HA increases in serum and tissue fluids, and this HA appears to be
mainly LMWHA [24,33,55]. The normal range of HA in serum is
0.01–0.1 mg/ml, while in patients with liver injury the serum
concentration of HA reaches 0.1–0.3 mg/ml [63]. In murine
models of lung injury, the concentration of HA increased by 50%
and the size of the accumulated HA was approximately
5.4610
5 Da [28]. As the injury resolved, the concentration of
HA returned to basal levels and the size reverted to 1.4610
6–
3.1610
6 Da, [28,74] similar to the size of HA in the lungs of
control mice. These results show that following an insult, there is
an increase in the concentration of small hyaluronic acid
fragments. As the injury resolves, the concentration of HA
decreases and the size returns back to normal (.10
6 Da).
Figure 7. HMWHA and LMWHA have different effects on the
expression of CD44. PBMC were incubated in SFM, SFM with 300 mg/
ml HMWHA, or SFM with 300 mg/ml LMWHA for 5 days. The PBMC were
then fixed and stained for CD44. In all panels, nuclei are stained blue
with DAPI and bars are 20 mm. Arrows indicate fibrocytes and
arrowheads indicate non-fibrocyte cells. The figures represent one of
3 independent experiments.
doi:10.1371/journal.pone.0026078.g007
Figure 8. Anti-CD44 antibodies potentiate the differentiation
of monocytes to fibrocytes. Human PBMC were cultured in 2 mg/ml
anti-human anti-CD44, anti-CD43, or mouse IgG1 isotype control. After
5 days, the cells were air dried, fixed, stained, and the number of
fibrocytes was counted. The results are mean 6 SEM of percent control
(n=6 separate experiments). The number of fibrocytes per 2.5610
5
PBMC in controls was 350, 50, 350, 250, 450, and 50. * indicates p,0.05
compared to control, as determined by ANOVA with Dunnett’s post-
test). Using the Mann Whitney two-tailed t-test, 2 mg/ml anti-human
anti-CD44 antibodies significantly increases the number of fibrocytes
when compared to control with p,0.001.
doi:10.1371/journal.pone.0026078.g008
Figure 9. At 30 minutes, both LMWHA and HMWHA are
internalized by monocytes. Purified human monocytes were
incubated in SFM, SFM with 300 mg/ml LMWHA, or 300 mg/ml of
HMWHA for 30 minutes. The PBMC were stained with biotinylated
hyaluronic acid binding protein (HABP) and this was detected with
streptavidin-FITC. In all panels, nuclei are stained blue with DAPI and
bars are 20 mm. The figures represent one of the 3 independent
experiments.
doi:10.1371/journal.pone.0026078.g009
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LMWHA at an injured site would inhibit fibrocyte differentiation
and collagen deposition to allow macrophages to freely move
about the injured site to phagocytose debris and clear any
infectious agents. As wound healing progresses and the ratio of
HMWHA to LMWHA increases [27], the HMWHA will promote
monocyte to fibrocyte differentiation, leading to tissue repair with
the fibrocytes secreting ECM and also stimulating ECM
Figure 10. SAP inhibits HMWHA-induced fibrocyte differentiation and potentiates LMWHA-induced fibrocyte inhibition. (A) Human
PBMC were cultured in different concentrations of HMWHA with 0, 0.1, 0.3, 1, and 3 mg/ml of SAP. After 5 days, the cells were air dried, fixed, stained,
and the number of fibrocytes was counted. The results are mean 6 SEM of fibrocytes per 2.5610
5 PBMC (n=5 separate experiments, except n=11
separate experiments for HMWHA with no SAP). With no SAP, the difference between no treatment and 300 mg/ml HMWHA is significant with
p,0.01 (t-test). With 300 mg/ml HMWHA, adding 1 or 3 mg/ml SAP significantly decreases the number of fibrocytes with p,0.05 (ANOVA). Using the
non-parametric Mann Whitney two-tailed t-test, with no SAP, the difference between no treatment and 300 mg/ml HMWHA is significant with
p,0.05. With 300 mg/ml HMWHA, adding 1 or 3 mg/ml SAP significantly decreases the number of fibrocytes with p,0.05. (B) Human PBMC were
cultured in different concentrations of LMWHA with 0, 0.1, 0.3, 1, and 3 mg/ml of SAP for 5 days. After 5 days, the cells were air dried, fixed, stained,
and the number of fibrocytes was counted. The results are mean 6 SEM of fibrocytes per 2.5610
5 PBMC (n=5 separate experiments, except n=11
separate experiments for LMWHA with no SAP). With no added SAP, the difference between no treatment and 100 mg/ml or 300 mg/ml LMWHA is
significant with p,0.001 (t-test). Using the non-parametric Mann Whitney two-tailed t-test, with no added SAP, the difference between no treatment
and 100 mg/ml or 300 mg/ml LMWHA is significant with p,0.05.
doi:10.1371/journal.pone.0026078.g010
Figure 11. LMWHA inhibits IL-4 or IL-13-induced fibrocyte differentiation. Human PBMC were cultured in (A) SFM, SFM with 1 ng/ml IL-4,
SFM with 300 mg/ml LMWHA, or SFM with 1 ng/ml IL-4 and 300 mg/ml LMWHA, or (B) SFM, SFM with 1 ng/ml IL-13, or SFM with 1 ng/ml IL-13 and
300 mg/ml LMWHA. After 5 days, the cells were air dried, fixed, stained, and the number of fibrocytes was counted. The results are mean 6 SEM of
percent control (n=3 separate experiments). The number of fibrocytes per 2.5610
5 PBMC in controls from the 3 donors was 900, 1520, and 431.
* indicates p,0.05, ** p,0.01, and *** p,0.001 compared to control as determined by t-test. Using the non-parametric Mann Whitney two-tailed t-
test, there is no significant difference among control, 300 mg/ml LMWHA, 1 ng/ml IL-4, 1 ng/ml IL-13, the combination of 300 mg/ml LMWHA and
1 ng/ml IL-4, or the combination of 300 mg/ml LMWHA and 1 ng/ml IL-13. Using the non-parametric Mann Whitney one-tailed t-test, 300 mg/ml
LMWHA significantly decreases the number of fibrocytes when compared to control with p,0.05. Also, the combination of 300 mg/ml LMWHA and
1 ng/ml IL-4 significantly decreases the number of fibrocytes when compared to 1 ng/ml IL-4 with p,0.05. The combination of 300 mg/ml LMWHA
and 1 ng/ml IL-13 also significantly decreases the number of fibrocytes when compared to 1 ng/ml IL-13 with p,0.05.
doi:10.1371/journal.pone.0026078.g011
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known mechanism to explain how a simple repeating disaccharide
of varying length has opposing effects on a same type of cell.
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